
Chinese General Practice ›› 2025, Vol. 28 ›› Issue (32): 4047-4054.DOI: 10.12114/j.issn.1007-9572.2025.0070
Special Issue: 心血管最新文章合辑
• Original Research • Previous Articles Next Articles
Received:2025-04-02
Revised:2025-05-20
Published:2025-11-15
Online:2025-09-23
Contact:
LIANG Wenjian
通讯作者:
梁文坚
作者简介:作者贡献:
陈慧龙负责统计学分析、论文撰写,并承担部分研究方法的设计任务;廖芸楚、刘育伟共同协助分析数据与撰写论文;孔政辉、黄兴辉、徐嘉辉进行数据申请与预处理;漆娜、王远平共同完成研究图表的设计与绘制;梁文坚提出主要研究目标,负责研究的构思与设计,进行论文的修订;所有作者对文章进行了最终的审阅和校对。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2025.0070
| 组别 | 例数 | 年龄(岁) | RFM | BMI (kg/m2) | 体质量(kg) | 腰围(cm) | 性别[例(%)] | 婚姻状况[例(%)] | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 女 | 男 | 已婚并与配偶同居 | 未婚/分居/丧偶 | |||||||
| 无CVD组 | 11 171 | 59.0±9.6 | 32.4±8.6 | 23.3±3.8 | 58.5±11.5 | 84.8±10.0 | 5 753(51.50) | 5 418(48.50) | 9 753(87.31) | 1 418(12.69) |
| CVD组 | 1 696 | 62.6±9.3 | 34.8±8.5 | 24.4±4.2 | 61.1±12.6 | 88.4±11.1 | 997(58.79) | 699(41.21) | 1 415(83.43) | 281(16.57) |
| χ2(t)值 | 14.64a | 10.69a | 9.98a | 8.03a | 12.60a | 31.34 | 19.29 | |||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||
| 组别 | 受教育程度[例(%)] | 居住地[例(%)] | 吸烟[例(%)] | 饮酒[例(%)] | ||||||
| 高中及以上 | 初中 | 小学 | 小学以下 | 农村 | 城市 | 无 | 有 | 有 | 无 | |
| 无CVD组 | 1 186(10.62) | 2 270(20.32) | 4 535(40.60) | 3 180(28.47) | 1 168(10.46) | 10 003(89.54) | 6 677(59.77) | 4 494(40.23) | 2 904(26.00) | 8 267(74.00) |
| CVD组 | 194(11.44) | 329(19.40) | 715(42.16) | 458(27.00) | 307(18.10) | 1 389(81.90) | 1 044(61.56) | 652(38.44) | 286(16.86) | 1 410(83.14) |
| χ2(t)值 | 3.54 | 84.81 | 1.96 | 65.87 | ||||||
| P值 | 0.316 | <0.001 | 0.162 | <0.001 | ||||||
| 组别 | 糖尿病[例(%)] | 高血压[例(%)] | 血脂异常[例(%)] | 心脏病[例(%)] | 卒中[例(%)] | |||||
| 无 | 有 | 无 | 有 | 无 | 有 | 无 | 有 | 无 | 有 | |
| 无CVD组 | 9 890(88.53) | 1 281(11.47) | 7 041(63.03) | 4 130(36.97) | 7 222(64.65) | 3 949(35.35) | 11 171(100.00) | 0 | 11 171(100.00) | 0 |
| CVD组 | 1 349(79.54) | 347(20.46) | 659(38.86) | 1 037(61.14) | 860(50.71) | 836(49.29) | 233(13.74) | 1 463(86.26) | 1 405(82.84) | 291(17.16) |
| χ2(t)值 | 107.74 | 358.04 | 122.53 | 10 872.53 | 1 961.07 | |||||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||
Table 1 Comparison of the basic information of the subjects between the CVD and non-CVD groups
| 组别 | 例数 | 年龄(岁) | RFM | BMI (kg/m2) | 体质量(kg) | 腰围(cm) | 性别[例(%)] | 婚姻状况[例(%)] | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 女 | 男 | 已婚并与配偶同居 | 未婚/分居/丧偶 | |||||||
| 无CVD组 | 11 171 | 59.0±9.6 | 32.4±8.6 | 23.3±3.8 | 58.5±11.5 | 84.8±10.0 | 5 753(51.50) | 5 418(48.50) | 9 753(87.31) | 1 418(12.69) |
| CVD组 | 1 696 | 62.6±9.3 | 34.8±8.5 | 24.4±4.2 | 61.1±12.6 | 88.4±11.1 | 997(58.79) | 699(41.21) | 1 415(83.43) | 281(16.57) |
| χ2(t)值 | 14.64a | 10.69a | 9.98a | 8.03a | 12.60a | 31.34 | 19.29 | |||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||
| 组别 | 受教育程度[例(%)] | 居住地[例(%)] | 吸烟[例(%)] | 饮酒[例(%)] | ||||||
| 高中及以上 | 初中 | 小学 | 小学以下 | 农村 | 城市 | 无 | 有 | 有 | 无 | |
| 无CVD组 | 1 186(10.62) | 2 270(20.32) | 4 535(40.60) | 3 180(28.47) | 1 168(10.46) | 10 003(89.54) | 6 677(59.77) | 4 494(40.23) | 2 904(26.00) | 8 267(74.00) |
| CVD组 | 194(11.44) | 329(19.40) | 715(42.16) | 458(27.00) | 307(18.10) | 1 389(81.90) | 1 044(61.56) | 652(38.44) | 286(16.86) | 1 410(83.14) |
| χ2(t)值 | 3.54 | 84.81 | 1.96 | 65.87 | ||||||
| P值 | 0.316 | <0.001 | 0.162 | <0.001 | ||||||
| 组别 | 糖尿病[例(%)] | 高血压[例(%)] | 血脂异常[例(%)] | 心脏病[例(%)] | 卒中[例(%)] | |||||
| 无 | 有 | 无 | 有 | 无 | 有 | 无 | 有 | 无 | 有 | |
| 无CVD组 | 9 890(88.53) | 1 281(11.47) | 7 041(63.03) | 4 130(36.97) | 7 222(64.65) | 3 949(35.35) | 11 171(100.00) | 0 | 11 171(100.00) | 0 |
| CVD组 | 1 349(79.54) | 347(20.46) | 659(38.86) | 1 037(61.14) | 860(50.71) | 836(49.29) | 233(13.74) | 1 463(86.26) | 1 405(82.84) | 291(17.16) |
| χ2(t)值 | 107.74 | 358.04 | 122.53 | 10 872.53 | 1 961.07 | |||||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||
| 组别 | 模型1 | 模型2 | 模型3 | |||
|---|---|---|---|---|---|---|
| OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
| RFM | 1.03(1.03~1.04) | <0.001 | 1.04(1.03~1.05) | <0.001 | 1.03(1.02~1.04) | <0.001 |
| RFM | ||||||
| Q1组 | ||||||
| Q2组 | 1.56(1.33~1.83) | <0.001 | 1.56(1.33~1.83) | <0.001 | 1.26(1.07~1.49) | 0.006 |
| Q3组 | 1.58(1.34~1.85) | <0.001 | 1.93(1.64~2.28) | <0.001 | 1.78(1.47~2.16) | <0.001 |
| Q4组 | 2.17(1.86~2.52) | <0.001 | 2.39(2.03~2.80) | <0.001 | 1.81(1.49~2.19) | <0.001 |
| P趋势值 | <0.001 | <0.001 | <0.001 | |||
Table 2 Multivariate Logistic regression analysis of the association between RFM and CVD
| 组别 | 模型1 | 模型2 | 模型3 | |||
|---|---|---|---|---|---|---|
| OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
| RFM | 1.03(1.03~1.04) | <0.001 | 1.04(1.03~1.05) | <0.001 | 1.03(1.02~1.04) | <0.001 |
| RFM | ||||||
| Q1组 | ||||||
| Q2组 | 1.56(1.33~1.83) | <0.001 | 1.56(1.33~1.83) | <0.001 | 1.26(1.07~1.49) | 0.006 |
| Q3组 | 1.58(1.34~1.85) | <0.001 | 1.93(1.64~2.28) | <0.001 | 1.78(1.47~2.16) | <0.001 |
| Q4组 | 2.17(1.86~2.52) | <0.001 | 2.39(2.03~2.80) | <0.001 | 1.81(1.49~2.19) | <0.001 |
| P趋势值 | <0.001 | <0.001 | <0.001 | |||
| 组别 | 模型1 | 模型2 | 模型3 | |||
|---|---|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
| RFM | 1.03(1.02~1.03) | <0.001 | 1.03(1.02~1.03) | <0.001 | 1.03(1.02~1.04) | <0.001 |
| RFM | ||||||
| Q1'组 | ||||||
| Q2'组 | 1.50(1.29~1.74) | <0.001 | 1.48(1.28~1.72) | <0.001 | 1.31(1.12~1.52) | 0.006 |
| Q3'组 | 1.22(1.05~1.43) | 0.010 | 1.31(1.12~1.53) | <0.001 | 1.34(1.12~1.61) | 0.002 |
| Q4'组 | 1.96(1.70~2.26) | <0.001 | 1.97(1.70~2.28) | <0.001 | 1.79(1.49~2.14) | <0.001 |
| P趋势值 | <0.001 | <0.001 | <0.001 | |||
Table 3 Multivariate Cox regression analysis of RFM and the risk of new-onset CVD
| 组别 | 模型1 | 模型2 | 模型3 | |||
|---|---|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
| RFM | 1.03(1.02~1.03) | <0.001 | 1.03(1.02~1.03) | <0.001 | 1.03(1.02~1.04) | <0.001 |
| RFM | ||||||
| Q1'组 | ||||||
| Q2'组 | 1.50(1.29~1.74) | <0.001 | 1.48(1.28~1.72) | <0.001 | 1.31(1.12~1.52) | 0.006 |
| Q3'组 | 1.22(1.05~1.43) | 0.010 | 1.31(1.12~1.53) | <0.001 | 1.34(1.12~1.61) | 0.002 |
| Q4'组 | 1.96(1.70~2.26) | <0.001 | 1.97(1.70~2.28) | <0.001 | 1.79(1.49~2.14) | <0.001 |
| P趋势值 | <0.001 | <0.001 | <0.001 | |||
| 组别 | 模型1 | 模型2 | 模型3 | |||
|---|---|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
| RFM与新发心脏病风险的Cox回归分析 | ||||||
| RFM | 1.03(1.03~1.04) | <0.001 | 1.03(1.03~1.04) | <0.001 | 1.03(1.02~1.04) | <0.001 |
| RFM | ||||||
| Q1'组 | ||||||
| Q2'组 | 1.48(1.24~1.78) | <0.001 | 1.46(1.22~1.75) | <0.001 | 1.32(1.09~1.59) | 0.008 |
| Q3'组 | 1.47(1.23~1.76) | <0.001 | 1.56(1.29~1.88) | <0.001 | 1.61(1.30~2.00) | <0.001 |
| Q4'组 | 2.20(1.86~2.61) | <0.001 | 2.23(1.87~2.65) | <0.001 | 2.07(1.67~2.57) | <0.001 |
| RFM与新发卒中风险的Cox回归分析 | ||||||
| RFM | 1.01(1.01~1.02) | 0.008 | 1.01(1.01~1.02) | 0.006 | 1.02(1.01~1.03) | 0.020 |
| RFM | ||||||
| Q1'组 | ||||||
| Q2'组 | 1.69(1.34~2.14) | <0.001 | 1.69(1.33~2.14) | <0.001 | 1.40(1.10~1.79) | 0.006 |
| Q3'组 | 0.91(0.69~1.18) | 0.463 | 0.97(0.74~1.28) | 0.835 | 1.02(0.75~1.40) | 0.882 |
| Q4'组 | 1.60(1.27~2.03) | <0.001 | 1.55(1.21~1.98) | <0.001 | 1.36(1.01~1.84) | 0.044 |
| 将RFM在0.5和99.5百分位数处进行缩尾处理后进行Cox回归分析 | ||||||
| RFM | 1.03(1.02~1.03) | <0.001 | 1.03(1.02~1.03) | <0.001 | 1.03(1.02~1.04) | <0.001 |
| RFM | ||||||
| Q1'组 | ||||||
| Q2'组 | 1.51(1.30~1.76) | <0.001 | 1.50(1.29~1.74) | <0.001 | 1.32(1.13~1.54) | <0.001 |
| Q3'组 | 1.22(1.04~1.42) | 0.013 | 1.30(1.11~1.52) | 0.001 | 1.33(1.11~1.60) | 0.002 |
| Q4'组 | 1.96(1.70~2.26) | <0.001 | 1.97(1.70~2.29) | <0.001 | 1.79(1.49~2.15) | <0.001 |
| 删除随访前2年新发CVD患者后进行Cox回归分析 | ||||||
| RFM | 1.02(1.02~1.03) | <0.001 | 1.03(1.02~1.04) | <0.001 | 1.03(1.02~1.04) | <0.001 |
| RFM | ||||||
| Q1'组 | ||||||
| Q2'组 | 1.40(1.18~1.66) | <0.001 | 1.39(1.17~1.64) | <0.001 | 1.22(1.03~1.45) | 0.025 |
| Q3'组 | 1.12(0.94~1.33) | 0.211 | 1.22(1.02~1.47) | 0.030 | 1.23(1.00~1.52) | 0.052 |
| Q4'组 | 1.85(1.57~2.17) | <0.001 | 1.91(1.62~2.26) | <0.001 | 1.70(1.38~2.09) | <0.001 |
Table 4 Sensitivity analyses of RFM and the risk of new-onset CVD
| 组别 | 模型1 | 模型2 | 模型3 | |||
|---|---|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
| RFM与新发心脏病风险的Cox回归分析 | ||||||
| RFM | 1.03(1.03~1.04) | <0.001 | 1.03(1.03~1.04) | <0.001 | 1.03(1.02~1.04) | <0.001 |
| RFM | ||||||
| Q1'组 | ||||||
| Q2'组 | 1.48(1.24~1.78) | <0.001 | 1.46(1.22~1.75) | <0.001 | 1.32(1.09~1.59) | 0.008 |
| Q3'组 | 1.47(1.23~1.76) | <0.001 | 1.56(1.29~1.88) | <0.001 | 1.61(1.30~2.00) | <0.001 |
| Q4'组 | 2.20(1.86~2.61) | <0.001 | 2.23(1.87~2.65) | <0.001 | 2.07(1.67~2.57) | <0.001 |
| RFM与新发卒中风险的Cox回归分析 | ||||||
| RFM | 1.01(1.01~1.02) | 0.008 | 1.01(1.01~1.02) | 0.006 | 1.02(1.01~1.03) | 0.020 |
| RFM | ||||||
| Q1'组 | ||||||
| Q2'组 | 1.69(1.34~2.14) | <0.001 | 1.69(1.33~2.14) | <0.001 | 1.40(1.10~1.79) | 0.006 |
| Q3'组 | 0.91(0.69~1.18) | 0.463 | 0.97(0.74~1.28) | 0.835 | 1.02(0.75~1.40) | 0.882 |
| Q4'组 | 1.60(1.27~2.03) | <0.001 | 1.55(1.21~1.98) | <0.001 | 1.36(1.01~1.84) | 0.044 |
| 将RFM在0.5和99.5百分位数处进行缩尾处理后进行Cox回归分析 | ||||||
| RFM | 1.03(1.02~1.03) | <0.001 | 1.03(1.02~1.03) | <0.001 | 1.03(1.02~1.04) | <0.001 |
| RFM | ||||||
| Q1'组 | ||||||
| Q2'组 | 1.51(1.30~1.76) | <0.001 | 1.50(1.29~1.74) | <0.001 | 1.32(1.13~1.54) | <0.001 |
| Q3'组 | 1.22(1.04~1.42) | 0.013 | 1.30(1.11~1.52) | 0.001 | 1.33(1.11~1.60) | 0.002 |
| Q4'组 | 1.96(1.70~2.26) | <0.001 | 1.97(1.70~2.29) | <0.001 | 1.79(1.49~2.15) | <0.001 |
| 删除随访前2年新发CVD患者后进行Cox回归分析 | ||||||
| RFM | 1.02(1.02~1.03) | <0.001 | 1.03(1.02~1.04) | <0.001 | 1.03(1.02~1.04) | <0.001 |
| RFM | ||||||
| Q1'组 | ||||||
| Q2'组 | 1.40(1.18~1.66) | <0.001 | 1.39(1.17~1.64) | <0.001 | 1.22(1.03~1.45) | 0.025 |
| Q3'组 | 1.12(0.94~1.33) | 0.211 | 1.22(1.02~1.47) | 0.030 | 1.23(1.00~1.52) | 0.052 |
| Q4'组 | 1.85(1.57~2.17) | <0.001 | 1.91(1.62~2.26) | <0.001 | 1.70(1.38~2.09) | <0.001 |
| [1] |
国家心血管病中心,中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2023概要[J]. 中国循环杂志,2024,39(7):625-660.
|
| [2] |
|
| [3] |
Risk Factor Collaboration(NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022:a pooled analysis of 3663 population-representative studies with 222 million children,adolescents,and adults[J]. Lancet,2024,403(10431):1027-1050. DOI:10.1016/S0140-6736(23)02750-2.
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [1] | YI Shanye, YANG Rong, LIAO Xiaoyang, ZHOU Yiheng, LIU Lidi, YANG Ziyu, BAI Jiaxin, JIA Yu, ZHANG Xin. Interpretation of the 2024 Blood Pressure Measurement and Assessment of Arterial Structure and Function: an Expert Group Position Paper [J]. Chinese General Practice, 2026, 29(32): 4690-4694. |
| [2] | ZHANG Panpan, ZHANG Zixin, WU Xinyu, HAN Quanle, ZHAO Li, YANG Jing, LI Lei, LI Xuyang, ZHANG Boheng, WU Shouling. A Retrospective Cohort Study on the Fatty Liver Index and Metabolic Dysfunction-associated Fatty Liver Disease in Healthy Populations [J]. Chinese General Practice, 2026, 29(31): 4582-4588. |
| [3] | FU Xiaoya, YANG Fei, GU Keyi, GU Handong, WANG Weiqiang. Correlation between Relative Fat Mass Index and Decreased Glomerular Filtration Rate in Patients with Cardiometabolic Comorbidities [J]. Chinese General Practice, 2026, 29(28): 4187-4192. |
| [4] | JIANG Chen, AN Ni, XU Yunjing, NIU Shaona, LI Fengming, JIANG Liangmei. A Cross-sectional Study of Hospitalization Characteristics and Healthcare Resource Consumption of Patients with Cardiovascular-kidney-metabolic Syndrome [J]. Chinese General Practice, 2026, 29(28): 4172-4178. |
| [5] | LU Hongrun, ZHANG Rui, ZHAO Yu, LI Jiazhen, WANG Weiqiang. Association of Cardiometabolic Comorbidity with Estimated Glomerular Filtration Rate [J]. Chinese General Practice, 2026, 29(28): 4179-4186. |
| [6] | GUO Junchi, ZHANG Mingyan, QIN Guangning, XU Qiang, LU Meijuan. Preliminary Application of the Novel Biomarker TANS01 in Cardiovascular Risk Assessment among Individuals with Phlegm-dampness Constitution [J]. Chinese General Practice, 2026, 29(27): 3924-3930. |
| [7] | ZHAO Yuanyuan, LIU Pulin, DAI Juan, ZHANG Gang, ZHANG Wei, ZHANG Xiaoxia, DENG Qing, YAN Yaqiong. Association Study between Chinese Visceral Adiposity Index and Risk of All-cause and Cause-specific Mortality in the Elderly [J]. Chinese General Practice, 2026, 29(26): 3781-3787. |
| [8] | YANG Rui, LIAO Xiaoyang, HUANG Chuanying, YANG Ziyu, SHEN Can, JIA Yu, LIU Lidi, YANG Rong. Interpretation of the 2024 British and Irish Hypertension Society Position Statement: Investigation and Management of Hypertension in Young People [J]. Chinese General Practice, 2026, 29(26): 3726-3732. |
| [9] | LI Xiaoxue, YIN Lihua, SU Xu, ZHANG Fuyan, ZHAN Qingqing, AN Qinyu, WANG Huiqun, LIU Tao, TAN Shisheng. Association between Dietary Quality and Risk of Hypertension: a Study Based on the 2022 Version of the Chinese Dietary Balance Index [J]. Chinese General Practice, 2026, 29(25): 3631-3639. |
| [10] | DONG Ao, ZHAO Naihui, OU Wenli, CHEN Shuohua, WANG Guodong, DAI Luyao, LIU Canzhang, WU Shouling, YANG Xiuhong. Association between Cardiometabolic Index and the Incident Chronic Kidney Disease: a Prospective Cohort Study [J]. Chinese General Practice, 2026, 29(25): 3614-3623. |
| [11] | ZHANG Wenzheng, ZHANG Hongling. Association between Cardiometabolic Index and Hypertension in Elderly Patients with Metabolic Associated Fatty Liver Disease in the Community Population: a Prospective Cohort Study [J]. Chinese General Practice, 2026, 29(23): 3261-3267. |
| [12] | CHAI Zhihao, ZHANG Weisen, LUO Jiaoling, ZHU Feng, ZHU Tong, JIN Yali, PAN Jing, LU Yingjun, JIANG Chaoqiang. The Mediation Effect of Socioeconomic Status in Childhood Parental Literacy and Cognitive Function in Middle-aged and Older People: Based on Guangzhou Biobank Cohort Study [J]. Chinese General Practice, 2026, 29(21): 2959-2966. |
| [13] | HAN Congcong, QIU Xinyu, SHAN Chunfang, SONG Ning, CHEN Qingjie, MULADILI· Abudureheman, LI Xiaomei, YANG Yining, ZHAO Qian. Impact of Metabolic Obesity Phenotype on Long-term Prognosis after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome [J]. Chinese General Practice, 2026, 29(21): 2950-2958. |
| [14] | LIU Shuai, YUAN Shizhao, LIU Yan, JIA Shuoxian, ZHAO Yan, WANG Ziyi, ZHOU Chunhua, YU Jing. Evaluation of the Efficacy, Safetyand Economy of Different Amphotericin B Formulationsin Invasive Fungal Disease: a Retrospective Cohort Study [J]. Chinese General Practice, 2026, 29(21): 2967-2974. |
| [15] | REYILAI· Maimaiti, ZHOU Yiran, WU Yun, LIU Zhencheng, LU Yaoqin, WU Haiyan. Association between Novel Obesity Indicators and Cardiovascular Disease Risk in Hypertensive Patients [J]. Chinese General Practice, 2026, 29(20): 2836-2845. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||